<DOC>
	<DOC>NCT02664805</DOC>
	<brief_summary>To compare the efficacy of twice daily applications of LEO 124249 ointment with LEO 124249 ointment vehicle for up to 8 weeks in the treatment of subjects with chronic hand eczema.</brief_summary>
	<brief_title>Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema</brief_title>
	<detailed_description />
	<mesh_term>Eczema</mesh_term>
	<criteria>Clinical diagnosis of chronic hand eczema with or without atopic etiology/background with a history of not adequately controlled disease activity with cutaneously applied steroid Physician's Global Assessment of disease severity graded as at least mild at Visit 1 In overall good health including well controlled diseases Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), retinoids (e.g. alitretinoin) or corticosteroids within 6 weeks prior to randomization (inhaled or intranasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used). PUVA (Psoralen Ultraviolet A) or UVB (Ultraviolet B) therapy on the hands within 4 weeks prior to randomization Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids on the hands within 2 weeks prior to randomization. Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to randomization Concurrent skin diseases on the hands Current diagnosis of exfoliative dermatitis Significant clinical infection (impetiginized hand eczema) on the hands which requires antibiotic treatment A marked abnormal ECG at baseline Known hepatic dysfunction or hepatic dysfunction tested at Screening Current participation in any other interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>